Comprehensive Stock Comparison
Compare Virax Biolabs Group Limited (VRAX) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  PHGE | Beta 0.93 vs VRAX's 1.24 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PHGE | -48.8% vs VRAX's -84.6% |
| Efficiency (ROA) | PHGE | -142.8% ROA vs VRAX's -199.1%, ROIC -305.2% vs -273.2% |
Who Each Stock Is For
Income & stability
PHGEbeta 0.93
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
PHGE-99.7% 10Y total return vs VRAX's -99.9%
Sleep-well-at-night portfolio
VRAXLower volatility, beta 1.24, Low D/E 6.9%, current ratio 7.27x
Defensive / Recession hedge
PHGEBeta 0.93, current ratio 2.48x
Business Model
What each company does and how it makes money
Virax Biolabs Group is a biotechnology company focused on viral disease prevention, detection, and management through diagnostic test kits and medical technology products. It generates revenue primarily from selling diagnostic tests—including rapid antibody, antigen, and PCR tests under the ViraxClear brand—and medical/PPE products under the ViraxCare brand, distributed through clinics, pharmacies, hospitals, and an online platform. The company's competitive advantage lies in its integrated portfolio spanning diagnostics and protective equipment for viral diseases, serving both healthcare institutions and corporate clients across multiple international markets.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRAX 2PHGE 2VRAX1/1 metricsVRAX5/9 metricsPHGE6/6 metricsPHGE2/2 metricsVRAX leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). PHGE leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Financial Metrics (TTM)
VRAX and PHGE operate at a comparable scale, with $162,750 and $0 in trailing revenue.
| Metric | VRAXVirax Biolabs Gro… | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $162,750 | $0 |
| EBITDAEarnings before interest/tax | -$12M | -$6M |
| Net IncomeAfter-tax profit | -$13M | -$37M |
| Free Cash FlowCash after capex | -$13M | -$28M |
| Gross MarginGross profit ÷ Revenue | -1.5% | — |
| Operating MarginEBIT ÷ Revenue | -77.8% | — |
| Net MarginNet income ÷ Revenue | -78.6% | — |
| FCF MarginFCF ÷ Revenue | -77.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -98.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +55.6% | -6.5% |
Valuation Metrics
| Metric | VRAXVirax Biolabs Gro… | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $2M | $82.8B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.11x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 245.06x | — |
| Price / BookPrice ÷ Book value/share | 0.12x | 3427.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
VRAX delivers a -2.3% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-4 for PHGE. VRAX carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHGE's 0.40x. On the Piotroski fundamental quality scale (0–9), PHGE scores 3/9 vs VRAX's 1/9, reflecting mixed financial health.
| Metric | VRAXVirax Biolabs Gro… | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -3.6% |
| ROA (TTM)Return on assets | -199.1% | -142.8% |
| ROICReturn on invested capital | -2.7% | -3.1% |
| ROCEReturn on capital employed | -111.4% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.07x | 0.40x |
| Net DebtTotal debt minus cash | -$4M | -$8M |
| Cash & Equiv.Liquid assets | $4M | $18M |
| Total DebtShort + long-term debt | $377,004 | $10M |
| Interest CoverageEBIT ÷ Interest expense | -149.04x | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in PHGE five years ago would be worth $47 today (with dividends reinvested), compared to $11 for VRAX. Over the past 12 months, PHGE leads with a -48.8% total return vs VRAX's -84.6%. The 3-year compound annual growth rate (CAGR) favors PHGE at -59.1% vs VRAX's -68.4% — a key indicator of consistent wealth creation.
| Metric | VRAXVirax Biolabs Gro… | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -45.6% | +194.4% |
| 1-Year ReturnPast 12 months | -84.6% | -48.8% |
| 3-Year ReturnCumulative with dividends | -96.8% | -93.2% |
| 5-Year ReturnCumulative with dividends | -99.9% | -99.5% |
| 10-Year ReturnCumulative with dividends | -99.9% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -68.4% | -59.1% |
Risk & Volatility
PHGE is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than VRAX's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHGE currently trades 42.8% from its 52-week high vs VRAX's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRAXVirax Biolabs Gro… | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 0.93x |
| 52-Week HighHighest price in past year | $1.58 | $14.71 |
| 52-Week LowLowest price in past year | $0.19 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 320K | 1.3M |
Analyst Outlook
| Metric | VRAXVirax Biolabs Gro… | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 22 | Mar 26 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | 100 | 0.12 | -99.9% |
| BiomX Inc. (PHGE) | 100 | 2.95 | -97.0% |
BiomX Inc. (PHGE) returned -100% over 5 years vs Virax Biolabs Group… (VRAX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | $99876.00 | $6331.00 | -93.7% |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
Chart 3EPS Growth — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -0.7 | -1.95 | -178.6% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
Chart 4Free Cash Flow — 5 Years
Virax Biolabs Group Limited generated $-5M FCF in 2025 (-776% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
VRAX vs PHGE: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — VRAX or PHGE?
Over the past 5 years, BiomX Inc. (PHGE) delivered a total return of -99.5%, compared to -99.9% for Virax Biolabs Group Limited (VRAX). A $10,000 investment in PHGE five years ago would be worth approximately $47 today (assuming dividends reinvested). Over 10 years, the gap is even starker: PHGE returned -99.7% versus VRAX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — VRAX or PHGE?
By beta (market sensitivity over 5 years), BiomX Inc. (PHGE) is the lower-risk stock at 0.93β versus Virax Biolabs Group Limited's 1.24β — meaning VRAX is approximately 35% more volatile than PHGE relative to the S&P 500. On balance sheet safety, Virax Biolabs Group Limited (VRAX) carries a lower debt/equity ratio of 7% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — VRAX or PHGE?
BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -957.4% for Virax Biolabs Group Limited — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -973.4% for VRAX. At the gross margin level — before operating expenses — PHGE leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — VRAX or PHGE?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is VRAX or PHGE better for a retirement portfolio?
For long-horizon retirement investors, BiomX Inc. (PHGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.93)). Both have compounded well over 10 years (PHGE: -99.7%, VRAX: -99.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between VRAX and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.